
	Webcast of the analyst conference call regarding the publication of the 9-Months 2011 result on November 11, 2011 at 2:30 pm CET
	MediGene Initiates Clinical Formulation Study of RhuDex® for the Oral Treatment of Autoimmune Diseases more

	MediGene and EIP Eczacibasi Enter Agreement for the Commercialization of Veregen® in Turkey more

	MediGene: Veregen® Marketing Approval Process Initiated for 17 Additional European Countries more

	MediGene Presents Overall Survival Data from a Phase II Trial of EndoTAG®-1 in Triple-Negative Breast Cancer (TNBC) more

Drugs for the market

MediGene's vision is the expansion of the potentials in medicine
by means of utilizing biotechnology in a responsible manner.
We apply state-of-the-art technologies in the development of
innovative drugs for the treatment of cancer and autoimmune
diseases.